Phase 2, Phase 3 Recruiting NIH
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer f…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05987241
Locations: - Cancer Center at Saint Joseph's — Phoenix, Arizona
- Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- University of Arizona Cancer Center-Orange Grove Campus — Tucson, Arizona
+ 483 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of decreased number of radiation (ultra-hypofractionated) treatments to the usual radiation number of treatments (hypofractionation) with standard of care chemotherapy, with cisplatin, gemcitabine o…
Sponsor: NRG Oncology
NCT ID: NCT07097142
Locations: - Mercy Hospital Fort Smith — Fort Smith, Arkansas
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- UC San Diego Moores Cancer Center — La Jolla, California
+ 208 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of improvemen…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07000084
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Mayo Clinic Hospital in Arizona — Phoenix, Arizona
+ 53 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in c…
Sponsor: Eli Lilly and Company
NCT ID: NCT07218380
Locations: - Clearview Cancer Institute — Huntsville, Alabama
- The University of Arizona Cancer Center - North Campus — Tucson, Arizona
- Chao Family Comprehensive Cancer Center and Ambulatory Care (CIACC) - Irvine — Irvine, California
+ 53 more sites in the U.S.
Phase 3 Recruiting Industry
A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
Sponsor: Ferring Pharmaceuticals
NCT ID: NCT06510374
Locations: - University of South Alabama (USA) Health System - USACM — Mobile, Alabama
- Urology Associates of Mobile — Mobile, Alabama
- Mayo Clinic Arizona — Phoenix, Arizona
+ 36 more sites in the U.S.
Phase 3 Recruiting Industry
The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06319820
Locations: - Arkansas Urology — Little Rock, Arkansas
- Genesis Research LLC — Los Alamitos, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
+ 35 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07106762
Locations: - Local Institution - 0167 — Gilbert, Arizona
- Local Institution - 0162 — Fullerton, California
- Local Institution - 0252 — Palo Alto, California
+ 30 more sites in the U.S.
Phase 3 Recruiting Industry
The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T1 achieved a complete response (CR) at 3 months. In this trial, the safety and …
Sponsor: Ferring Pharmaceuticals
NCT ID: NCT06545955
Locations: - American Institute of Research — Los Angeles, California
- USC Kenneth Norris Jr Cancer Hospital — Los Angeles, California
- University of California, Irvine — Orange, California
+ 30 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
This is a global, multicenter, randomized, open-label, Phase 2/3 study of Dato-DXd plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin in participants with la/mUC who progressed during or after EV plus pembrolizu…
Sponsor: Daiichi Sankyo
NCT ID: NCT07129993
Locations: - Research Site — Fullerton, California
- Research Site — La Jolla, California
- Research Site — San Francisco, California
+ 26 more sites in the U.S.
Phase 3 Recruiting Industry
The main purpose of this study is to compare the disease-free survival (the length of time after randomization that a participant survives without any signs or symptoms of the cancer returning, or progressing) between Bacillus Calmette-Gué…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06919965
Locations: - Colorado Clinical Research — Lakewood, Colorado
- Georgia Urology — Atlanta, Georgia
- Associated Urological Specialists — Chicago Ridge, Illinois
+ 17 more sites in the U.S.
Phase 3 Recruiting Academic/Other
The purpose of this study is to look at two standard surgical techniques used during a radical cystectomy and see whether they influence outcomes such as length of stay in the hospital and infections after surgery. This trial will evaluate…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06703476
Locations: - Memorial Sloan Kettering at Basking Ridge (Consent Only) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Consent Only) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Consent Only) — Montvale, New Jersey
+ 4 more sites in the U.S.
Phase 3 Recruiting Industry
This is a phase III, single-arm, multicenter, international study to assess the efficacy and safety of ONCOFID-P-B following intravesical instillation in adult patients with histologically and cytologically confirmed CIS, with or without c…
Sponsor: Fidia Farmaceutici s.p.a.
NCT ID: NCT05024773
Locations: - Banner Health- MD Anderson Cancer Center — Gilbert, Arizona
- Ochsner Clinic Foundation — New Orleans, Louisiana
- Johns Hopkins Kimmel Cancer Center — Baltimore, Maryland
+ 3 more sites in the U.S.